12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cimzia certolizumab pegol: Additional Phase III data

Additional data from the double-blind, Japanese Phase III HIKARI trial in 230 patients who had an inadequate response to or were unable to take methotrexate showed that 200 mg Cimzia every 2 weeks significantly improved ACR20 response rate, the primary endpoint, at weeks 12 and 24 vs. placebo (67.2% and 63.8%, respectively, vs. 14.9% and 11.4%)....

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >